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Downsizing the BAD BH3 peptide to small constrained
a-helices with improved ligand efficiency†
Nicholas E. Shepherd,⇤a Rosemary S. Harrison,a Gloria Ruiz-Gomez,a,b Giovanni
Abbenante,a Jody M. Masonc and David P. Fairlie⇤a
Bcl2 Homology (BH) proteins can either trigger or prevent programmed cell death or apoptosis.
Deregulation of the BH protein family network leads to evasion of apoptosis, uncontrolled prolifer-
ation and is a hallmark of cancer. Inhibition of pro-survival BH proteins is a promising chemothera-
peutic strategy for certain cancers. We have examined whether helix-constrained peptides based
on the BAD BH3 domain (residues 103–127) can be downsized to much smaller more drug-like
peptides. We report the preparation, structural characterisation, in vitro Bcl-xL inhibition and
leukemic T-cell killing ability of 45 linear, mono-, bi- and tricyclic helical peptidomimetics between
8- and 19-residues in length. We show that the BAD BH3 can be downsized to 8–14 residues and
still maintain appreciable affinity for Bcl-xL. In addition, the binding efficiency indices (BEI) of the
downsized mimetics are significantly higher than the BAD BH3 and similar stapled BH3 mimetics,
approaching drug-like molecules. This suggests that bicyclic and monocyclic mimetics based on
BH3 domains are much more efficient binding ligands than the longer peptides which they mimic.
Introduction
The ability of cells to undergo apoptosis is vital for the survival of
an organism.1 Bcl2 homology (BH) proteins regulate this path-
way and are grouped into three sub-families. Pro-survival mem-
bers Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1/BFL-1 maintain the survival
signal within the cell. Pro-death affectors Bak and Bax directly
trigger cell death. Finally, BH3-only members BID, BAD, BIM,
BIK, EGl-1, BMF, PUMA, NOXA, BNIP3 and Beclin-1 indirectly
promote cell death.2 In the normal state, the network func-
tions by pro-survival proteins sequestering and inhibiting pro-
death function of Bak and Bax. When cellular or pathological
signals indicate irreparable cellular damage, BH3-only members
are produced to bind pro-survival proteins and displace Bak and
Bax.2 Released Bak/Bax then initiate apoptosis by oligomeris-
ing and inserting into the outer mitochondrial membrane lead-
ing to permeabilisation, cytochrome c release and eventually
cell death.2 Deregulation of this network occurs in cancer cells
through the over-production of pro-survival proteins that ensure
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Bak/Bax always remain sequestered even under cell damaging
conditions that should trigger apoptosis. This promotes tumor
growth by allowing diseased cells to either propagate3 or release
pro-inflammatory signals which protect the tumor from immune
surveillance.4 Evasion of apoptosis is a hallmark of cancer.5
Small molecules such as ABT-737,6 helix-constrained stapled
peptides7–10 and foldamers11 can mimic BH3-only members
by binding to over-abundant pro-survival proteins, releasing
Bak/Bax and reactivating apoptosis in cells. Crystal structures
of BH3 peptides and small molecules bound to Bcl-xL and Bcl-2
exist (Fig. 1A, B). For peptides, 3–4 hydrophobic residues and a
single acidic residue confer binding (Fig. 1B). One small molecule
ABT-199 (Venetoclax R ) has entered the clinic. There is intense
interest in developing other small molecules, stapled peptides and
foldamers to inhibit Bcl-2 proteins, reactivate apoptosis and treat
cancer.
Previously developed stapled peptides mimicked the entire BH3
domains of BID, BIM and BAD (>20 residues).7–10 Key binding
residues are, however, contained within a shorter 10-residue seg-
ment (3 helical turns). These peptides were preorganised into
an a-helix with a single hydrocarbon staple. Although substan-
tially helical, peptidic regions flanking the staple suffer from low
biological stability. Stapled BH3 peptides have equivalent activ-
ity to small molecules like ABT-737 but are 3–4 times higher in
molecular weight. We previously developed a strategy to sta-
blise very short peptides (5-residues) in highly a-helical struc-
tures using K(i)–D(i+4) lactam bridges.12 We demonstrated that
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this staple conferred much higher a-helicity than alternatives.13
Multiple such bridges incorporated in longer bioactive helical se-
quences allowed downsizing to just ‘hotspot’ binding regions. Re-
moving unnecessary appendages improves biological stability.14
Downsized versions of stapled BH3 peptides would also be easier
and cheaper to produce. Their smaller molecular weight would
make them more efficient binding ligands. Smaller molecules like
ABT-737 (Fig. 1D) replicate the biological activity of entire BH3
domains whilst only mimicking ⇠8 residues. Thus, reported long
stapled peptides should in principle be amenable to downsizing
provided peptides are a-helical and correctly position key side-
chains into complementary pockets on Bcl-xL. Here we describe
efforts to downsize the BAD BH3 domain.
Fig. 1 A) Crystal structure of ABT-737 (grey) bound to Bcl-xL (cyan) (pdb:
2yxj). B) Crystal structure of BAD(103–127) (red) bound to Bcl-xL (cyan)
(pdb: 1g5j). C) Overlay of bound structures of ABT737 and BAD(103–
127). D) Peptide sequence of BAD(103–127) and molecular structure of
ABT-737. Key residues for binding shown in orange, those mimicked by
ABT737 are indicated.
Results and discussion
Helix-stabilized and downsized versions of the BAD BH3 do-
main
We formulated three approaches to generate downsized and sta-
pled versions of residues 103–127 in the BAD BH3 (hereafter,
BAD 25-mer). Firstly, we made 19-, 12- and 8-residue peptides
based on the central portion of the BAD 25-mer15 containing a
single K(i)-D(i+4) lactam bridge (5–7). Secondly, we inserted
two K(i)–D(i+4) lactam bridges into the different fragments of
the BAD 25-mer. These 12–14 residue BAD mimics (8–11) at-
tempted to define a ‘hotspot’ within the sequence. Thirdly, we
removed six residues from the N-terminus of the BAD 25-mer to
give a 19-residue mimic with three helix inducing K(i)–D(i+4)
lactam constraints (12). Bridging positions were chosen based
on crystal structures and prior SAR data. Generally these were
positioned on the solvent exposed face of the helix. Linear pep-
tides corresponding to each of these regions were also prepared
(1–4). All peptide sequences are shown in Figure 2.
To determine the minimal functional region, we first investi-
gated the 25-residue BAD BH3 domain and four truncated linear
analogues (1–4, 13–19 residues; Fig. 2). We assessed structure
by CD spectroscopy (Fig. 3A) and binding to Bcl-xL by fluores-
Fig. 2 BAD BH3 (103–127) and linear and cyclic peptides (1–17)
synthesized in this study (Z = Norleucine, 1Nal = 1-Naphthylalanine,
Aib = a-aminoisobutyric acid, 2Nal = 2-Naphthylalanine, F(Cl2) = 3,4-
dichlorophenylalanine). Underlined region indicates minimal region mim-
icked by ABT-737. All peptides were N-acetylated and C-amidated.
cence polarization (FP, Fig. 3B). The BAD 25-mer and shortened
versions 1–4 all had little a-helical structure by CD spectroscopy
(Fig. 3A). In the Bcl-xL binding assay the BAD 25-mer effectively
competed with its fluorescently labeled derivative Flu-BAD (IC50
53 nM, Fig. 3B, red). Compounds 1–3 had IC50 > 100 µM, while
only the 19-residue 4 retained some binding (IC50 4.4 µM, Fig.
3B, orange).
K(i)–D(i+4) lactam bridges induce high a-helicity into short
unstructured peptides.12–14 Therefore, a lactam constraint was
inserted into peptide 4 in place of Arg8 and Glu12. These were
equivalent positions occupied by the hydrocarbon staple used in
previous studies.7–10 This peptide (5) and two truncated versions
(6 and 7) were all shorter than the BAD 25-mer by 5-, 12- and 19-
residues, respectively. CD spectral fingerprints revealed a slight
increase in a-helicity for 5 over the full length BAD 25-mer. The
shorter 6 and 7 had 2–2.5-fold improved a-helicity (Fig. 4A).
But peptides 5–7 all had weaker binding to Bcl-xL (Fig. 4B). The
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Fig. 3 A) CD spectra of BAD(103–127) and linear peptides 1–4. B)
Dose-response curves for synthetic compounds in a fluorescence po-
larization assay against Bcl-xL (error bars represent SEM, n   3).
BAD(103–127) ( ), 1 ( ), 2 ( ), 3 ( ), 4 ( ).
19-residue 5 was equipotent to its linear analogue 4 (IC50 of 4.6
µM), while peptides 5 and 6 had IC50 > 100 µM.
Fig. 4 A) CD spectra of BAD(103–127) and monocyclic peptides 5–7. B)
Dose-response curves for synthetic compounds in a fluorescence polar-
ization assay against Bcl-xL (error bars represent SEM, n  3). BAD(103-
127) ( ), 5 ( ), 6 ( ), 7 ( ).
Next, we incorporated two or three lactam bridges into 12–19
residue segments that spanned the entire BAD 25-mer (peptides
8–12). Introducing a second and third bridge peptides led to sub-
stantially improved a-helicity over linear sequences as judged by
CD spectra (2.6–6.2-fold, Fig. 5A). However, improved a-helicity
in these smaller peptides did not translate to improved binding
over the BAD 25-mer (Fig. 5B). Tricyclic 12 was the most po-
tent (IC50 252 nM) followed by the bicyclic 9 (IC50 1.5 µM) and
11 (IC50 40 µM). These results indicate the central portion of
the BAD BH3 helix (9) provides most of the binding energy. The
constrained C-terminal region (11) contributes a small amount
to binding. The N-terminal region (8) appears less important for
binding. The positioning of lactam bridges was critical. The back-
to-back staple arrangement in 10 abolished activity, likely due to
steric clashes.
Fig. 5 A) CD spectra of BAD(103–127) and bicyclic peptides 8–11 and
tricycle 12. B) Dose-response curves for synthetic compounds in a fluo-
rescence polarization assay against Bcl-xL (error bars represent SEM, n
  3). BAD(103-127) ( ), 8 ( ), 9 ( ), 10 ( ), 11 ( ), 12 ( ).
These data suggested that a-helicity was less important con-
tributor to inhibitor potency than peptide length. To probe this
relationship we compared helicity and activity across related pep-
tides 4, 5, and 12; 2, 6, and 9; and, 3 and 11. Helicity improved
inhibitory potency by 1–2 log units (Fig. 6). However, increasing
a-helicity did not compensate for loss of interacting sidechains
through downsizing. Bcl-xL appears to lack a defined ‘hot-spot’.
Interactions across the N-, central and C-terminal portions of the
BAD BH3 together provide high affinity.
Fig. 6 Relationship between fractional helicity and inhibitory potency for
linear and cyclic mimetics of the BAD-BH3 domain.
The activity of 9 (IC50 1.5 µM) was lower than for the BAD
25-mer, ABT-737 or reported compound SAH-BID.8 But we had
removed 11 residues from the BAD 25-mer and yet still retained
activity. Thus, we decided to compare the efficiency of our down-
sized ligands. We calculated the binding efficiency index16 (BEI)
to determine whether downsizing was worthwhile. Table 1 shows
the BEI of bicyclic 9 (3.55) was better than the BAD BH3 (2.32)
and SAH-BID (2.71) but worse than ABT-737 (9.23). We rea-
soned if 9 could be optimised to an IC50 to 40 nM without much
increase in molecular weight, the BEI would be 4.6. This is only
2-fold better than the BAD-25-mer, and still 2-fold worse than
ABT-737. Thus, it seemed prudent to find an even smaller lead
with a BEI closer to ABT-737.
Table 1 Comparison of compound binding efficiency indices (BEI) for Bcl-
xL
Compound MW pIC50 BEI*
BAD BH3 3134 7.3 2.32
5 2510 5.3 2.11
9 1633 5.8 3.55
12 2305 6.6 2.86
15 956 5.2 5.44
16 1043 5.2 4.99
17 1063 5.2 4.89
SAH-BID8 2726 7.4 2.71
ABT-7376 813 7.5 9.23
* Binding Efficiency Index (BEI) = pIC50 / MW (in kDa)
Monocycle library
ABT-737 mimics three side chains of the BAD BH3 domain:
Leu114, Met117 and Phe121. Therefore, we decided to prepare
monocyclic octapeptides spanning the Leu114–Phe121 region.
We prepared a small library of 26 compounds using macrocyclic
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octapeptide 7 as a scaffold. (Fig. 7A). Leu1 and Nle4 in 7 were
substituted with Phe or 1-Naphthylalanine (1Nal). Phe8 in 7 was
substituted with Nle or homophenylalanine (hPhe). Although 7
was essentially inactive, we hypothesized that incorporating aro-
matic groups to better resemble ABT-737 might improve activity.
Each compound was screened at 10 µM in the FP assay. Of these
compounds, 25 displaced less than 20% Flu-BAD. One compound
(13, IC50 7.9 µM) displaced 25% Flu-BAD BH3 and differed from
7 only in its first residue, 1Nal instead of Leu. The acyclic ana-
logue Ac-1Nal-RR-Nle-ADDF-NH2 (14) had IC50 36 µM (Fig 7B),
highlighting the importance of helix stabilization.
Fig. 7 A) Cyclic peptide library based on the BAD(114–121) region
(1Nal = 1-Naphthylalanine, hPhe = Homophenylalanine). Single con-
centration triplicate screen of the ability cyclic peptides [10 µM] to
displace fluorescein-labelled BAD(103–127) from Bcl-xL. B) Dose re-
sponse curves for BAD(103–127) ( ), Ac-1NalR[KNleADD]F-NH2 (13,
 ), and Ac-1NalRRADDF-NH2 (14,  ) in a fluorescence polarization as-
say against Bcl-xL (error bars represent SEM, n   3).
Next we attempted to improve the activity of 13. We re-
placed Arg2 with Aib to increase helicity within the N-terminal
exocyclic portion (15, Fig. 8, IC50 6.3 µM). We made N-
terminal substitutions with non-peptidic capping groups (1-
naphthylpropanoyl, 1-naphthylpropenoyl, 1-naphthyloxyacetyl)
or C-terminal substitutions with unnatural aromatic amino
acids (3,4-dichlorophenylalanine, Phe(Cl2); serine-O-benzyl es-
ter, Ser(OBn); and 2-Naphthylalanine, 2Nal). All N-terminal sub-
stitutions were less active, whilst Phe(Cl2) (16) and 2Nal (17) at
the C-terminus offered no improvement (IC50 5.8 and 7.0 µM,
Fig. 8).
The new leads 15–17 were now one third of the size of the
BAD 25-mer and SAH-BID. Despite having low micromolar ac-
tivity, they are more efficient ligands (BEI 4.89–5.44, Table 1).
Monocycles must still be optimised to equipotency with ABT-737
and SAH-BID. If achieved whilst maintaining their current molec-
ular weight (1000 Da), their BEI would be much more favourable
(⇠7.5). To show further potential of bicyclic 9 and monocyclic
15–17 as inhibitors of Bcl-xL/2 function, we evaluated leukemic
T-cell (Jurkat E6.1) killing abilities of 9 and 16 using an MTT as-
say. The linear BAD 25-mer showed weak activity (IC50 60 µM),
whilst 9 and 16 both showed improved cell killing ability with
IC50 40 and 18 µM, respectively (Fig. 9). Thus, the BAD 25-
mer can be downsized to smaller cyclic peptides with appreciable
binding to Bcl-xL and activity in cells.
Fig. 8 A) Cyclic peptide library based on the BAD(114–121) region
(Phe(Cl2) = 3,4-Dichlorophenylalanine, Ser(OBn) = Serine-O-benzyl es-
ter, 2Nal = 2-Naphthylalanine). Single concentration triplicate screen
of the ability cyclic peptides [10 µM] to displace fluorescein-labelled
BAD(103–127) from Bcl-xL. B) Dose response curves for BAD(103–127)
( ), Ac-1NalAib[KNleADD]F-NH2 (15,  ), Ac-1NalAib[KNleADD]F(Cl2)-
NH2 (16,  ), Ac-1NalAib[KNleADD]2Nal-NH2 (17,  )(error bars repre-
sent SEM, n   3).
Fig. 9 Dose-response curves of compounds in an MTT assay against
Jurkat E6.1 cells (error bars represent SEM, n   3). BAD BH3 (103–
127) ( ), bicyclic 9 ( ), and monocyclic 16 ( ).
Conclusion
Forty-five helix-stabilized and downsized analogues of the BAD
BH3 domain were structurally characterized by CD spectroscopy
and their in vitro inhibition of Bcl-xL was examined. Using one to
three K(i)–D(i+4) lactam bridges to constrain different regions
of the BAD BH3 domain, we have shown: i) the central portion
(residues 108–121) is the critical region for BAD BH3 activity; ii)
a-helicity is important for binding to Bcl-xL, conferring a 1–2 log
unit improvement in IC50; iii) the BAD BH3 can be downsized to
bicyclic and monocyclic mimics with low micromolar affinity for
Bcl-xL (e.g. 9, IC50 1.5 µM; 15–17, IC50 5.8–7 µM). Subtle differ-
ences in helicity or the helix constraint might contribute to lower
Bcl-xL affinity compared to SAH-BID8 and SAH-BIM.9 However,
the clear difference is the much smaller size of 9 (13-residues),
13, 15–17 (8-residues) relative to SAH-BID (23-residues) and
SAH-BIM (21-residues). Additional interactions with Bcl-xL likely
account for higher affinity for the longer peptides. Despite re-
duced activity, these downsized molecules are actually more effi-
cient ligands. Their binding efficiency indices are closer to ABT-
737 than full length BAD BH3 or stapled peptides such as SAH-
BID. Compounds 9 and 16 showed higher cell killing potency than
the BAD 25-mer. Overall bicyclic and monocyclic BH3 mimetics
identified here are promising candidates for optimisation as Bcl2-
protein inhibitors. These studies further demonstrate the utility of
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K(i)–D(i+4) lactam bridges for helix pre-organisation. Our work
provides a platform for investigating protein-protein interactions
and developing small, efficient peptidomimetic inhibitors.
Experimental
General
Fmoc-amino acids were purchased from Novabiochem (Mel-
bourne, Australia) and Chemimpex (USA). O-Benzotriazole-
N,N,N’,N’-tetramethyluronium-hexafluorophosphate (HBTU) was
obtained from IRIS Biotech GmbH (Marktredwitz, Germany)
and Chemimpex (USA). HCTU was purchased from Chemimpex
(USA). HATU was purchased from Chemimpex (USA). All other
reagents were of peptide synthesis grade and obtained from Aus-
pep (Melbourne, Australia).
Molecular modelling
Crystal structures were visualised using MacPymol.17 The PISA
server18 was used to assist characterising protein-protein interac-
tions.
Peptide synthesis and purification
Peptides were synthesized manually by standard solid phase
methods using HBTU/DIPEA activation of Fmoc on Rink Amide
resins (substitution 0.3–0.5 mmol/g, 0.2–0.5 mmol scale). 4
equiv of Fmoc-protected amino acid, 4 equiv of HBTU and 4
equiv of DIPEA were used in each coupling. Fmoc deprotec-
tion involved 2⇥3 min treatments with excess piperidine/DMF
(1:1). Coupling yields were monitored by quantitative ninhydrin
assay. Arginine residues were double coupled to prevent dele-
tions within the sequence. After the final (N-terminal) residue
was coupled, the compound was acetyl capped with 2 equiv acetic
acid, 2 equiv HBTU and 2 equiv DIPEA respectively. For cyclic
peptides the phenylisopropyl ester of aspartic acid and methyl-
trityl group of lysine were removed by treating the peptide resin
with 3% TFA, 2.5% TIPS in DCM (5⇥2 min). The resin was neu-
tralised by washing with 5% DIPEA in DMF (2⇥3 min). Cycliza-
tion was affected on-resin using BOP, DIPEA in DMF. Fluorescein-
labelled BAD (Flu-BAD) was synthesised as above omitting the
cyclisation and capping procedures. After the final glutamine was
coupled the peptide was deprotected and Fmoc-6-aminohexanoic
acid (AHA) was coupled analogously to other amino acids. Fol-
lowing subsequent Fmoc-deprotection, four molar equivalents of
5(6)-carboxyfluorescein and DIC were coupled overnight. After
synthesis the peptide resins were washed with DMF, MeOH/DCM
and DCM, dried under nitrogen with suction for 20 min. Peptides
were cleaved using 95% TFA, 2.5% TIPS, 2.5% H2O. Peptides
were precipitated with diethyl ether and then decanted to give
white solids that were re-dissolved in 1:1 acetonitrile/water and
lyophilised. The crude peptides were purified by rp-HPLC (Vydac
C18 column, 300 Å 22⇥250 mm, 214 nm, Solvent A=0.1% TFA
in H2O, Solvent B=0.1% TFA, 10% H2O in acetonitrile. Gradi-
ent: 0% B to 70% B over 35 min). Peptides were characterised by
analytical rp-HPLC and ESI-MS and in all cases were >92% pure.
Circular dichroism
CD experiments were performed on a Jasco Model J-
710 spectropolarimeter routinely calibrated with (1S)-(+)-10-
camphorsulfonic acid. Spectra were recorded in a 0.1 cm Jasco
cell between 260 and 185 nm at 50 nm/min with a bandwidth
of 1.0 nm, response time of 2 s, resolution step width of 0.1 nm,
and sensitivity of 20, 50, or 100 mdeg. Each spectrum represents
the average of five scans with smoothing to reduce noise. Peptide
samples for CD spectroscopy were dissolved in 18 MW distilled
water (⇠3-4 mg/mL). 500 µL of each stock solution was then
diluted 1:1 with phosphate buffer pH 7.4. Solutions were then
prepared for each sample with final concentrations ranging from
50 to 800 µM in 10 mM sodium phosphate buffer (pH 7.4). Over
this concentration range the CD intensity was found to be inde-
pendent of concentration ruling out aggregation as a stabilizing
effect. The remaining 500 µL from the initial stock solution was
used for accurate concentration determination. Accurate concen-
trations of stock solutions were determined by 1D 1H NMR spec-
troscopy based on integrations of non-exchangeable proton sig-
nals using the PULCON method.19 Briefly 475 µL of the initial
peptide stock solution was mixed with 50 µL of D2O and spiked
with an internal standard, 25 µL of 10.077 mM DSS. 1D 1H NMR
spectra were then recorded with gradient water suppression and a
relaxation delay (d1) of 30 s to allow for full relaxation of peptide
and DSS 1H signals to facilitate accurate integration of proton sig-
nals with S/N > 250:1. Fractional helicity was calculated using
the equation derived by Luo et. al.20
Fluorescence polarisation assay
Assays were conducted as previously described.21 Briefly, the
assay buffer contained 20 mM phosphate buffer, 50 mM
NaCl, 1 mM EDTA and 0.05% pluronic F-127 (Invitrogen,
CA, USA) and the fluorescent probe Flu-BAD (fluorescein-
AHA-NLWAAQRYGRELRRNleSDEFFVDSFKK-NH2, AHA = 6-
aminohexanoic acid). The equilibrium binding experiments of the
fluorescein-labelled BAD peptide to Bcl-xL (R&D Systems) was
determined in a 96-well assay plate contained 15 nM fluorescent
peptide, and increasing concentrations of protein in assay buffer
in a final volume of 200 µL. The plate was incubated for 20 min
and then measured using Envision plate reader (Perkin Elmer)
at room temperature with an excitation wavelength of 480 nm
and an emission wavelength of 535 nm. Millipolarisation units
(mP) were calculated using the equation below by the Envision
software:
mP=
S  (G⇥P)
(S  (G⇥P))⇥1000
where S and P are background subtracted fluorescence rates
and G is an instrument and assay dependent factor (determined
for each plate). Kd values were calculated by fitting data to a sig-
moidal dose-response nonlinear regression model (equation be-
low) using GraphPad Prism (GraphPad Software Inc., San Diego,
CA). The competition studies were performed in a 96-well plate
containing 15 nM fluorescein-labelled BAD, 10 nM Bcl-xL and in-
creasing concentrations of test compounds in assay buffer, in a
final volume of 200 µL. The plate was incubated at room temper-
+PVSOBM/BNF<ZFBS>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ature for 20 min and then measured as described above. The IC50,
or the concentration at which 50% of bound peptide is displaced,
was obtained by fitting the data to a sigmoidal dose-response non-
linear regression model (Prism5, GraphPad Software):
Y =
bottom(top bottom)
1+10(logEC50 X)⇥hillslope
Cell culture
The human leukaemia T cell line (Jurkat E6.1 cells) were cultured
in GIBCO R  RPMI (Invitrogen, CA, USA) medium supplemented
with 10% FBS (Invitrogen, CA, USA), GIBCO R  Pen/Strep (50
units/mL penicillin and 50 µg/ml streptomycin, Invitrogen, CA,
USA), GIBCO R  NEAA (non-essential amino acids; 1⇥, Invitro-
gen, CA, USA) and GIBCO R  L-glutamic acid (final concentration
2 mM, Invitrogen, CA, USA). Cells were grown to 80-90% con-
fluency at 37  C (5% CO2) and were passaged at a ratio of 1:10
every three to four days.
Cytotoxicity assay
To assess the cytotoxicity of peptides on Jurkat E6.1 cells, we used
the standard MTT assay. In this assay, the yellow tetrazolium salt
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) can be reduced to a purple formazan product in the mi-
tochondria of metabolically active cells. We were able to quantity
the formation of blue formazan at 570 nm, relating absorbance to
the number of viable cells. We expected that the peptides would
have different stability in serum so to minimise this effect, the
MTT assays were conducted in serum-free media. Jurkat T cells
were washed three times in serum-free media and subsequently
plated into a clear, flat-bottom, 96-well microtitre plate at 5⇥104
cells/well. Cells were then treated with 10 µL of peptide at var-
ious concentrations. The microtitre plate was then incubated for
48 hours at 37  C (5% CO2). MTT (Sigma-Aldrich, NY, USA) was
added to each well (10 µL, final concentration 50 µg/mL). The
treated plate was incubated in the dark for two hours at 37  C
(5% CO2). 10% SDS in water/isopropanol (1:1) was added (100
µL per well) and incubated at 37  C overnight, to allow complete
solubilisation of the purple formazan product. Absorbance was
read at 570 nm, with background subtraction 630–690 nm, on
BioTekPowerWave XS micro-well plate reader. A dose-response
curve was obtained by fitting data to a sigmoidal dose-response
nonlinear regression model (Prism5, GraphPad Software).
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A) Crystal structure of ABT-737 (grey) bound to Bcl-xL (cyan) (pdb: 2yxj). B) Crystal structure of BAD(103-
127) (red) bound to Bcl-xL (cyan) (pdb: 1g5j). C) Overlay of bound structures of ABT737 and BAD(103-
127). D) Peptide sequence of BAD(103-127) and molecular structure of ABT-737. Key residues for binding 
shown in orange, those mimicked by ABT737 are indicated.  
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Fig. 2 BAD BH3 (103–127) and linear and cyclic peptides (1–17) synthesized in this study (Z = Norleucine, 
1Nal = 1-Naphthylalanine, Aib = alpha-aminoisobutyric acid, 2Nal = 2-Naphthylalanine, F(Cl2) = 3,4- 
dichlorophenylalanine). Underlined region indicates minimal region mimicked by ABT-737. All peptides were 
N-acetylated and C-amidated.  
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Fig. 3 A) CD spectra of BAD(103–127) and linear peptides 1–4. B) Dose-response curves for synthetic 
compounds in a fluorescence polarization assay against Bcl-xL (error bars represent SEM, n > 3). BAD(103–
127) (red), 1 (green), 2 (blue), 3 (magenta), 4 (orange).  
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Fig. 4 A) CD spectra of BAD(103–127) and monocyclic peptides 5–7. B) Dose-response curves for synthetic 
compounds in a fluorescence polarization assay against Bcl-xL (error bars represent SEM, n > 3). BAD(103-
127) (red), 5 (orange), 6 (blue), 7 (magenta).  
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Fig. 5 A) CD spectra of BAD(103–127) and bicyclic peptides 8–11 and tricycle 12. B) Dose-response curves 
for synthetic compounds in a fluorescence polarization assay against Bcl-xL (error bars represent SEM, n > 
3). BAD(103–127) (red), 8 (green), 9 (blue), 10 (cyan), 11 (magenta), 12 (orange).  
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Fig. 6 Relationship between fractional helicity and inhibitory potency for linear and cyclic mimetics of the 
BAD-BH3 domain.  
 
69x50mm (300 x 300 DPI)  
 
 
Page 16 of 22Organic & Biomolecular Chemistry
  
 
 
Fig. 7 A) Cyclic peptide library based on the BAD(114–121) region (1Nal = 1-Naphthylalanine, hPhe = 
Homophenylalanine). Single concentration triplicate screen of the ability cyclic peptides [10 mM] to displace 
fluorescein-labelled BAD(103–127) from Bcl-xL. B) Dose response curves for BAD(103–127) (red ), Ac-
1NalR[KNleADD]F-NH2 (13,  blue), and Ac-1NalRRADDF-NH2 (14, magenta ) in a fluorescence 
polarization assay against Bcl-xL (error bars represent SEM, n > 3).  
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Fig. 8 A) Cyclic peptide library based on the BAD(114–121) region (Phe(Cl2) = 3,4-Dichlorophenylalanine, 
Ser(OBn) = Serine-O-benzyl ester, 2Nal = 2-Naphthylalanine). Single concentration triplicate screen of the 
ability cyclic peptides [10 mM] to displace fluorescein-labelled BAD(103–127) from Bcl-xL. B) Dose response 
curves for BAD(103–127) (red ), Ac-1NalAib[KNleADD]F-NH2 (15, cyan ), Ac-1NalAib[KNleADD]F(Cl2)-
NH2 (16, green ), Ac-1NalAib[KNleADD]2Nal-NH2 (17, magenta ) (error bars represent SEM, n > 3).  
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Fig. 9 Dose-response curves of compounds in an MTT assay against Jurkat E6.1 cells (error bars represent 
SEM, n > 3). BAD BH3 (103–127) (red ), bicyclic 9 (blue ), and monocyclic 16 (purple ).  
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TOC Entry: The BAD BH3 domain was downsized into small efficient macrocycles with affinity for Bcl-xL.  
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Table 1. Compound characterisation data 
# Sequence [M+H]+ 
Calc. 
[M+H]+ 
Found 
HPLC  
Rt 
BAD-
BH3 
Ac-NLWAAQRYGRELRRMSDEFVDSFKK- 
NH2 
3142.59 3142.97 14.67 
Flu-BAD Flu-AHA-
NLWAAQRYGRELRRMSDEFVDSFKK- NH2 
3571.05 3571.34 14.34 
1 Ac-NLWAAQRYGRELRRNle-NH2 1943.25 1943.11 14.17 
2 Ac-QRYGRELRRNleSDEF-NH2 1866.08 1866.67 14.68 
3 Ac-LRRNleSDEFVDSFKK-NH2 1781.05 1780.59 14.53 
4 Ac-QRYGRELRRNleSDEFVDSFKK-NH2 2570.90 2570.55 14.25 
5 Ac-QRYGRELR[KNleSDD]FVDSFKK-NH2- 2510.85 2510.32 14.58 
6 Ac-YARELR[KNleADD]F-NH2 1518.79 1518.64 14.75 
7 Ac-LR[KNleADD]F-NH2 999.04 999.55 15.33 
8 Ac-[KNLWD]AQ[KYARD]L-NH2 1625.86 1625.21 15.04 
9 Ac-[KYARD]LR[KMADD]F-NH2 1632.89 1632.44 15.22 
10 Ac-Y[KRELD][KMADD]F-NH2 1534.72 1535.26 15.81 
11 Ac-LR[KNleADD]FV[KSFKD]-NH2 1685.93 1686.03 15.38 
12 Ac-[KYGRD]LR[KNleSDD]FV[KSFKD]-NH2 2304.64 2305.28 15.29 
13 Ac-1NalR[KNleADD]F-NH2 1083.55 1083.53 15.74 
14 Ac-1NalRRNleADEF-NH2 1143.58 1143.89 14.74 
15 Ac-1Nal Aib[KNleADD]F-NH2 955.48 955.66 16.31 
16 Ac-1Nal Aib[KNleADD]Phe(Cl2)-NH2 1042.88 1042.51 16.02 
17 Ac-1Nal Aib[KNleADD]2Nal-NH2 1062.52 1063.34 16.35 
18 Ac-LR[KNleADD]hPhe-NH2 1013.57 1012.97 15.24 
19 Ac-LR[KFADD]hPhe-NH2 1047.55 1046.86 15.55 
20 Ac-LR[K1NalADD]hPhe-NH2 1047.55 1046.86 15.24 
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21 Ac-FR[KNleADD]hPhe-NH2 1047.55 1047.59 15.56 
22 Ac-FR[KFADD]hPhe-NH2 1081.53 1081.49 15.55 
23 Ac-FR[K1NalADD]hPhe-NH2 1131.55 1131.40 16.11 
24 Ac-1NalR[KNleADD]hPhe-NH2 1097.51 1097.57 16.16 
25 Ac-1NalR[KFADD]hPhe-NH2 1131.45 1131.55 16.11 
26 Ac-1NalR[K1NalADD]hPhe-NH2 1181.38 1181.56 16.74 
27 Ac-LR[KFADD]F-NH2 1033.53 1032.91 15.18 
28 Ac-LR[K1NalADD]F-NH2 1083.55 1082.84 15.89 
29 Ac-FR[KNleADD]F-NH2 1033.53 1033.65 15.23 
30 Ac-FR[KFADD]F-NH2 1067.61 1067.52 15.24 
31 Ac-FR[K1NalADD]F-NH2 1117.53 1117.41 15.77 
32 Ac-1NalR[KFADD]F-NH2 1117.53 1117.51 15.65 
33 Ac-1NalR[K1NalADD]F-NH2 1167.55 1167.33 16.19 
34 Ac-LR[KNleADD]Nle-NH2 965.57 965.81 15.21 
35 Ac-LR[KFADD]Nle -NH2 999.55 999.72 15.01 
36 Ac-LR[K1NalADD]Nle -NH2 1049.57 1049.65 15.80 
37 Ac-FR[KNleADD]Nle -NH2 999.55 999.66 15.17 
38 Ac-FR[KFADD]Nle -NH2 1033.53 1033.61 14.98 
39 Ac-FR[K1NalADD]Nle -NH2 1083.55 1083.51 15.56 
40 Ac-1NalR[KNleADD]Nle -NH2 1049.57 1049.38 16.67 
41 Ac-1NalR[KFADD]Nle -NH2 1083.55 1083.66 15.61 
42 Ac-1NalR[K1NalADD]Nle -NH2 1133.22 1133.57 16.24 
43 Ac-1NapCH2CH2CO-Aib[KNleADD]Nle -NH2 955.66 955.48 16.72 
44 Ac-1NapCHCHCO-Aib[KFADD]Nle -NH2 953.46 953.85 16.95 
45 Ac-1NapOCH2CO-Aib[K1NalADD]Nle -NH2 1028.88 1028.51 16.61 
HPLC conditions: Phenomenex C18 column, 5µm 100 Å 4.6×250 mm, 214 nm, Solvent A=0.1% 
TFA in H2O, Solvent B=0.1% TFA, 10% H2O in acetonitrile. Gradient: 0% B to 100% B over 30 
min). 
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